Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.36M | $9.73M | $22.5M | $7.87M | — | — | — | — | — |
| Revenue growth | — | 16.4% | 131.1% | -65.0% | — | — | — | — | — |
| Operating income | -$26.2M | -$36.0M | -$32.2M | -$82.2M | -$75.6M | -$148M | -$208M | -$276M | -$333M |
| Operating margin | -312.8% | -369.9% | -143.0% | -1044.3% | — | — | — | — | — |
| Net income | -$25.5M | -$34.5M | -$31.8M | -$74.8M | -$72.3M | -$140M | -$192M | -$256M | -$329M |
| Net margin | -304.9% | -354.8% | -141.5% | -950.4% | — | — | — | — | — |
| EPS (diluted) | -$2.51 | -$1.39 | -$4.18 | -$16.17 | -$1.87 | -$1.73 | -$1.94 | -$1.94 | -$2.16 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.8M | -$32.5M | -$41.5M | -$35.9M | -$58.8M | -$119M | -$154M | -$208M | -$264M |
| Capital expenditures | $912K | $549K | $33.0K | — | $1.72M | $6.86M | $2.80M | $573K | $1.55M |
| Free cash flow | -$26.7M | -$33.0M | -$41.5M | — | -$60.5M | -$126M | -$156M | -$208M | -$266M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $28.3M | $55.7M | $37.4M | $242M | $220M | $140M | $53.2M | $98.2M | $312M |
| Total assets | $49.1M | $85.9M | $49.4M | $251M | $232M | $301M | $313M | $328M | $938M |
| Total liabilities | $20.8M | $25.7M | $17.7M | $16.2M | $17.9M | $45.1M | $55.6M | $71.6M | $301M |
| Long-term debt | — | — | — | — | — | — | — | — | $223M |
| Shareholders' equity | -$48.8M | $60.2M | $31.8M | $235M | $214M | $256M | $258M | $256M | $636M |
| Retained earnings | -$51.3M | -$92.1M | -$124M | -$199M | -$271M | -$411M | -$604M | -$859M | -$1.19B |
| Shares (wtd avg diluted) | 10.2M | 30.1M | 7.67M | 32.3M | 38.7M | 58.7M | 79.7M | 104M | 129M |
Every figure is extracted from Cogent Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.